FDA Approves OXYCODONE HYDROCHLORIDE — Genus Lifesciences Inc.
Genus Lifesciences Inc. received FDA approval on October 20, 2010, for OxyCODONE HYDROCHLORIDE (NDA200535), a move expected to bolster the generic market for this critical analgesi…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Genus Lifesciences Inc. received FDA approval on October 20, 2010, for OxyCODONE HYDROCHLORIDE (NDA200535), a move expected to bolster the generic market for this critical analgesi…
# FDA Approves Strides Pharma's Generic Losartan Potassium Tablet Strides Pharma Science Limited received FDA approval for its generic losartan potassium 25 mg tablet, expanding t…
# FDA Approves Lupin Pharmaceuticals' Generic Losartan Potassium Lupin Pharmaceuticals, Inc. received FDA approval for its generic losartan potassium oral formulation (ANDA078232)…
Hikma Pharmaceuticals USA Inc. secured FDA approval to manufacture the generic form of Oxymorphone Hydrochloride, an oral analgesic, providing a cost-effective alternative to brand…
PAI Holdings, LLC has received FDA approval for its ANDA for buprenorphine hydrochloride, solidifying its position in the critical opioid addiction treatment market and increasing …
On July 30, 2010, Merz Pharmaceuticals, LLC received FDA approval for XEOMIN (incobotulinumtoxin A), signaling a new entrant in the botulinum toxin type A market that is poised to …
On July 16, 2010, Amneal Pharmaceuticals received FDA approval for new drug application 090606, a strategic move that positions the firm to expand its generic portfolio and capture…
Knoa Pharma LLC secured FDA approval for its BUTRANS transdermal patch, expanding the market for long-acting opioid delivery systems in the chronic pain management sector.
Moments ago, ANI PHARMS announced FDA approval for its generic version of the unnamed substance, expected to broaden the company’s revenue streams and drive market share expansion …
Strides Pharma Science Limited announced the successful launch of oral Mycophenolate Mofetil (ANDA090055) to compete in this critical cardiovascular market. Entering the generics s…
Walgreens received FDA approval on June 2 for a generic topical acne treatment containing Adapalene, a move expected to intensify competition and price pressures within the dermato…
Amgen’s (NASDAQ: AMGN) approval of the subcutaneous DENOSUMAB formulation shows the biotech giant intends to leverage the format’s improved dosing convenience to untether the brand…
# FDA Approves Quagen Pharmaceuticals' Generic Valproic Acid Oral Formulation Quagen Pharmaceuticals LLC received FDA approval for its generic valproic acid oral formulation (ANDA…
On May 7, 2010, Barr Pharmaceuticals received approval for ANDA090360, paving the way for an Abbreviated New Drug Application (ANDA) that targets the generic sector related to the …
B. Braun Medical Inc. earned FDA approval today for Cefepime Hydrochloride and Dextrose Intravenous injection, a strategic addition to its hospital portfolio that positions the com…
ONESOURCE SPECIALTY received FDA approval for its ANDA, marking a strategic entry or expansion into the generic market that is anticipated to generate near-term revenue growth.
# FDA Approves Generic Drug for Teva Pharmaceutical Industries Teva Pharmaceutical Industries received FDA approval for a generic drug application (ANDA076958) on April 6, 2010, e…
# FDA Approves OxyContin Generic Formulation for Knoa Pharma Knoa Pharma LLC received FDA approval for its generic oxycodone hydrochloride oral formulation, potentially opening si…
# FDA Approves Actavis Pharma's Generic Diltiazem Extended-Release Formulation Actavis Pharma, Inc. received FDA approval for MATZIM LA (diltiazem hydrochloride), an extended-rele…
Hikma Pharmaceuticals USA Inc. announced the receipt of FDA approval for its Abbreviated New Drug Application (ANDA040881) for hydrocodone bitartrate and acetaminophen, enhancing i…